{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:47:48Z","timestamp":1793245668653,"version":"4.5.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lumanity Communications Inc"},{"DOI":"10.13039\/100016619","name":"MyoKardia Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target the hyper-contractile phenotype, which plays a critical role in the pathophysiology of the disease. In Phase 2 and 3 clinical trials, mavacamten was well tolerated, reduced left ventricular outflow tract gradients, improved exercise capacity and symptoms, and was associated with improvements in other clinically relevant parameters, such as patient-reported outcomes and circulating biomarkers. In addition, treatment with mavacamten was associated with evidence of favourable cardiac remodelling in multi-modality imaging studies. Mavacamten substantially reduced guideline eligibility for septal reduction therapy candidates with oHCM and drug-refractory symptoms. In this article, the available efficacy and safety data from completed and ongoing clinical studies of mavacamten in patients with symptomatic oHCM are reviewed. Longer term extension studies may help address questions related to the positioning of mavacamten in current oHCM management algorithms, interactions with background therapy, as well as the potential for disease modification beyond symptomatic relief of left ventricular outflow tract obstruction.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehad637","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T20:13:21Z","timestamp":1694722401000},"page":"4622-4633","source":"Crossref","is-referenced-by-count":164,"title":["Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3472-626X","authenticated-orcid":false,"given":"Eugene","family":"Braunwald","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women\u2019s Hospital , 60 Fenwood Road, Boston, MA 02115 , USA"},{"name":"Department Medicine, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P","family":"Abraham","sequence":"additional","affiliation":[{"name":"UCSF HCM Center of Excellence, University of California San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Meyer Children\u2019s Hospital, University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"key":"2023121815263868300_ehad637-B1","first-page":"e558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2023121815263868300_ehad637-B3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","article-title":"Targeting the sarcomere in inherited cardiomyopathies","volume":"19","author":"Lehman","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2023121815263868300_ehad637-B4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.CIR.20.2.181","article-title":"Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction","volume":"20","author":"Morrow","year":"1959","journal-title":"Circulation"},{"issue":"Suppl 4","key":"2023121815263868300_ehad637-B5","first-page":"3","article-title":"Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients","volume":"30","author":"Braunwald","year":"1964","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.amjcard.2016.02.044","article-title":"Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States","volume":"117","author":"Maron","year":"2016","journal-title":"Am J Cardiol"},{"key":"2023121815263868300_ehad637-B9","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B11","doi-asserted-by":"crossref","first-page":"e015473","DOI":"10.1161\/JAHA.119.015473","article-title":"Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a new era in clinical testing?","volume":"9","author":"Mazzarotto","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023121815263868300_ehad637-B12","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","article-title":"Time to think differently about sarcomere-negative hypertrophic cardiomyopathy","volume":"143","author":"Watkins","year":"2021","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B13","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9149(62)90373-9","article-title":"Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs","volume":"10","author":"Braunwald","year":"1962","journal-title":"Am J Cardiol"},{"key":"2023121815263868300_ehad637-B15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/01.CIR.29.3.422","article-title":"The circulatory response of patients with idiopathic hypertrophic subaortic stenosis to nitroglycerin and to the Valsalva maneuver","volume":"29","author":"Braunwald","year":"1964","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.37.1.8","article-title":"Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis","volume":"37","author":"Stewart","year":"1968","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2023121815263868300_ehad637-B18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12955-020-01604-9","article-title":"Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire","volume":"18","author":"Capota","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2023121815263868300_ehad637-B19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","article-title":"Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life","volume":"4","author":"Zaiser","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2023121815263868300_ehad637-B20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"2023121815263868300_ehad637-B21","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B23","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200002103420601","article-title":"Efficacy of implantable cardioverter defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"342","author":"Maron","year":"2000","journal-title":"N Engl J Med"},{"key":"2023121815263868300_ehad637-B25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0033-0620(68)90011-X","article-title":"Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis","volume":"11","author":"Cohen","year":"1968","journal-title":"Prog Cardiovasc Dis"},{"key":"2023121815263868300_ehad637-B26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC expert panel","volume":"180","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"2023121815263868300_ehad637-B27","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","article-title":"Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience","volume":"6","author":"Rastegar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"2023121815263868300_ehad637-B29","doi-asserted-by":"crossref","first-page":"e227293","DOI":"10.1001\/jamanetworkopen.2022.7293","article-title":"Association of septal myectomy with quality of life in patients with left ventricular outflow tract obstruction from hypertrophic cardiomyopathy","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023121815263868300_ehad637-B30","volume-title":"CAMZYOS\u2122 (Mavacamten) Prescribing Information","author":"Bristol Myers Squibb Company","year":"2022"},{"key":"2023121815263868300_ehad637-B31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"2023121815263868300_ehad637-B32","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"2023121815263868300_ehad637-B33","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023121815263868300_ehad637-B34","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca(2+)-sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023121815263868300_ehad637-B35","doi-asserted-by":"crossref","first-page":"e006853","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2023121815263868300_ehad637-B36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2023121815263868300_ehad637-B37","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B38","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"key":"2023121815263868300_ehad637-B39","article-title":"Pharmacokinetic drug-drug interaction study of mavacamten with verapamil in healthy subjects","volume":"11","author":"Perera","year":"2022","journal-title":"Clin Pharm Drug Dev"},{"key":"2023121815263868300_ehad637-B40","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"2023121815263868300_ehad637-B41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023121815263868300_ehad637-B42","first-page":"A13962","article-title":"Precision pharmacological treatment for obstructive hypertrophic cardiomyopathy with mavacamten: one-year results from PIONEER-OLE","volume":"140","author":"Heitner","year":"2019","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jacc.2022.01.005","article-title":"Assessment of disease status and treatment response with artificial intelligence-enhanced electrocardiography in obstructive hypertrophic cardiomyopathy","volume":"79","author":"Tison","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B45","author":"FDA Center for Drug Evaluation and Research"},{"key":"2023121815263868300_ehad637-B46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2023121815263868300_ehad637-B47","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2023121815263868300_ehad637-B48","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM CMR substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0735-1097(23)00770-2","article-title":"96 week cardiac magnetic resonance (CMR) results of treatment with mavacamten from the EXPLORER cohort of the Mava Long term Extension (LTE) study in patients with obstructive hypertrophic cardiomyopathy HCM)","volume":"81","author":"Saberi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B50","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"2023121815263868300_ehad637-B51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2023121815263868300_ehad637-B52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","article-title":"Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial","volume":"25","author":"Xie","year":"2022","journal-title":"J Med Econ"},{"key":"2023121815263868300_ehad637-B53","article-title":"Updated cumulative results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy","author":"Rader","journal-title":"Presented at the American College of Cardiology Annual Scientific Session"},{"key":"2023121815263868300_ehad637-B54","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32-weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"2023121815263868300_ehad637-B55","doi-asserted-by":"crossref","first-page":"e014986","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023121815263868300_ehad637-B56","author":"Reuters"},{"key":"2023121815263868300_ehad637-B57","author":"The National Institute for Health and Care Excellence (NICE)"},{"key":"2023121815263868300_ehad637-B58","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B59","author":"ClinicalTrials.gov"},{"key":"2023121815263868300_ehad637-B60","author":"ClinicalTrials.gov"},{"key":"2023121815263868300_ehad637-B61","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"2023121815263868300_ehad637-B62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41598-022-26630-z","article-title":"Effects of aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy","volume":"13","author":"Sharpe","year":"2023","journal-title":"Sci Rep"},{"key":"2023121815263868300_ehad637-B63","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","article-title":"A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants","volume":"7","author":"Malik","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"2023121815263868300_ehad637-B64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B65","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0735-1097(23)00768-4","article-title":"Long-term efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"81","author":"Saberi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023121815263868300_ehad637-B66"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/44\/4622\/54578883\/ehad637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/44\/4622\/54578883\/ehad637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T10:36:23Z","timestamp":1702895783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/44\/4622\/7296449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":66,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2023,10,7]]},"published-print":{"date-parts":[[2023,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad637","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,21]]},"published":{"date-parts":[[2023,10,7]]}}}